A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

NCT07040228 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer Metastatic

Interventions

DRUG: Regorafenib combined with Toripalimab and Albumin paclitaxel

Sponsor

Junjie Hang

Collaborators

[object Object]
[object Object]